Overview
- The European Medicines Agency’s CHMP issued a positive opinion for encorafenib (BRAFTOVI) combined with cetuximab and FOLFOX as a first‑line option for adults with BRAFV600E‑mutant metastatic colorectal cancer, and has forwarded that opinion to the European Commission for a final decision.
- BREAKWATER, the Phase 3 trial that underpinned the recommendation, reported improved objective response rates and a median progression‑free survival of 12.8 months versus 7.1 months for standard oxaliplatin‑based chemotherapy.
- An interim analysis from BREAKWATER showed a substantial overall survival advantage with median OS of 30.3 months versus 15.1 months, reflecting about a 51% reduction in the risk of death versus chemotherapy with or without bevacizumab.
- Trial safety was consistent with known drug profiles, with the most common treatment‑related side effects including nausea, anaemia, diarrhoea and decreased appetite.
- If the European Commission grants marketing authorisation later in 2026, the regimen would become the first BRAF‑targeted therapy approved for first‑line treatment of this high‑risk molecular subgroup and could change initial care options for affected patients.